MedTech Reimbursement Shift

Reimbursement has shifted from a background policy risk to a first-order commercial determinant across medtech and specialty pharma, with 141 mentions across 45 companies marking the structural arrival of payer-driven pricing architecture as a dealbreaker for product adoption and a persistent margin headwind. MDT's Symplicity Spyral conversion from coverage uncertainty to CMS-finalized national coverage with commercial payer expansion (Highmark named), PODD's addition of 6.5 million covered lives and prior-authorization simplification for 10 million lives in a single quarter, and VRTX's JOURNAVX reaching 260 million covered lives across three of four major Medicare Part D PBMs within the first year all demonstrate that reimbursement access is now a gating factor for volume ramp, not a downstream consideration. Simultaneously, structural reimbursement headwinds are permanent: AMGN realized a 22% net selling price decline for Enbrel in Q2 2026 under IRA Medicare Part D price-setting; NVO committed to 50% and 35% WAC reductions for Wegovy and Ozempic respectively effective January 1, 2027 via MFN agreement; ZBH is experiencing flat-to-100bp pricing erosion from CJR-X expansion and PFS rate cuts up to 20%; and NVST faces 45% price reductions in China's VBP 1 for implants (though volumes more than doubled). The forward indicator is whether CMS issues a national coverage decision for DXCM's type 2 non-insulin CGM before year-end 2026 and implements mid-2027, which would unlock 25 million patient opportunity and signal payer acceptance of preventive CGM in a non-insulin cohort.